Drug Trial Radar · NCT07029555
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
May 15, 2028
Study completion May 16, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).
Conditions
- Rheumatoid Arthritis
Interventions
PIT565Biological
Study treatment will be provided in vials as open-label participant specific supply.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 6 months
Locations
16 sites in 9 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Pilar, Buenos Aires, Argentina
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Leiden, South Holland, Netherlands
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.